News
3 High-Yield Tech Stocks to Buy in February
If the recent volatility in the stock market has you looking for less stressful alternatives and/or has made you curious about making a turn to investing in dividend-paying companies, you've come to
Is Alphabet the Best FAANG Stock for 2022?
The technology sector has seen more than its share of volatility and sell-offs over the past year, and yet some tech stocks are managing well against the headwinds of potential interest rate hikes
What's Next for Lockheed and Aerojet Rocketdyne Now That Their Deal Is Dead?
Lockheed Martin (NYSE: LMT) has formally pulled the plug on its planned $4.4 billion acquisition of Aerojet Rocketdyne Holdings (NYSE: AJRD), bowing to regulators who opposed the deal instead of
Why Abbvie Might Be Poised for a Return to Profitability
In this clip from "The Pharma & Biotech Show" on Motley Fool Live, recorded on Feb. 2, Motley Fool contributors Keith Speights and Brian Orelli assess the pharma giant's projection that it'll return
Intel Goes After Gamers AMD Abandoned
Intel (NASDAQ: INTC) has been losing market share to Advanced Micro Devices (NASDAQ: AMD) over the past few years. A combination of chronic manufacturing delays and other missteps at Intel, good
3 Reasons to Buy This Growth Stock With a $91 Billion Market on the Way
Confluent (NASDAQ: CFLT) reported its fourth-quarter earnings results on Feb. 10, blowing past analyst expectations. The company made $120 million in revenue, which topped estimates by $10 million
Sitting on Cash? These 2 Stocks Are Great Buys
Earnings season is in full swing, with many tech stocks reporting earnings in the past few weeks. With so many companies announcing their latest financial results, it might be hard to decide which
Will Tractor Supply's Rapid Growth Persist?
With fantastic recent quarterly results and a dividend just raised by a whopping 77%, Tractor Supply (NASDAQ: TSCO) has become a hot growth stock. In this episode of "3 Minute Stocks Updates" on
This Value Stock Is a Long-Term Market Beater
Don't look now, but value stocks are back in style -- with inflation and coming increases in interest rates as the culprit. Just to cite one example: The Vanguard Value ETF has outperformed the
Is Twitter Stock a Buy Now?
Twitter (NYSE: TWTR) posted its fourth-quarter earnings report on Feb. 10. The social media company's revenue grew 22% year over year to $1.57 billion, matching analysts' expectations. But its
2 Monster Dividend Stocks to Buy and Hold in 2022 (and Beyond)
Broadly speaking, companies that choose to pay a dividend tend to be financially stable -- especially those that consistently raise the payout over time. And that stability often translates into
2022 Will Be the Last Time This Social Security Change Happens
In most years, Social Security undergoes important changes. These include an annual benefits increase if a consumer price index shows costs going up, as well as an increase in how much income is
Are Brighter Times Ahead for HealthEquity Stock in 2022?
HealthEquity (NASDAQ: HQY) is the foremost provider of health savings accounts (HSAs) in the U.S., but the company got hit hard during the pandemic with an unfortunately timed major acquisition. In
Novavax Investors Can Finally Breathe a Sigh of Relief
Novavax (NASDAQ: NVAX) investors faced their fair share of volatility last year with the company's multiple EUA filing delays. In this clip from "The Pharma & Biotech Show" on Motley Fool Live
3 Cutting-Edge, Protein-Degrader Biotech Stocks to Watch
In this clip from "The Pharma & Biotech Show" on Motley Fool Live, recorded on Feb. 2, Motley Fool contributor Brian Orelli discusses the current drug developments of biotech companies and assesses
Inside Gilead's Lackluster $7.2 Billion Q4 Earnings
In this clip from "The Pharma & Biotech Show" on Motley Fool Live, recorded on Feb. 2, Motley Fool contributor Brian Orelli analyzes Gilead's (NASDAQ: GILD) earnings report and discusses why the
Why It's Time to Buy Moderna Stock Again
It's easy to pile on Moderna (NASDAQ: MRNA) these days. The sizzle from earlier in the pandemic has definitely fizzled. Moderna's current downtrend dates back to September 2021. The new year hasn't
3 Unstoppable Stocks That Could Create Lasting Generational Wealth
Investors should not look for life-changing returns in the stock market to come in a day or a year. Rather, the keys to generating powerful returns are patience and commitment. Patience is needed to
Shopify Has Plunged Recently -- Here's Why It Could Be a Buy Now
With shares down by more than 45% from the highs, Shopify (NYSE: SHOP) has certainly been an underperformer recently. However, in this Motley Fool Live video clip, recorded on Jan. 27, Fool.com
Should Investors Be Concerned About Starbucks Unionizing?
Since workers at two Starbucks (NASDAQ: SBUX) stores in Buffalo, New York, voted to unionize late last year, the labor movement has taken on growing momentum in the coffee chain, spreading to a
This Office REIT Just Bought 2 Apartment Buildings -- Here's Why
Empire State Realty Trust (NYSE: ESRT) has primarily owned office buildings for much of its history, but recently added New York City apartment buildings to the portfolio. In this Fool Live video
3 Investments to Buy With Your Tax Refund
Though we're pretty early on in this year's tax season, some filers might soon start seeing their refunds hit their bank accounts. If you're getting a pile of cash back from the IRS this year, you
Should Investors Buy PayPal After Its Recent Earnings Report?
PayPal Holdings (NASDAQ: PYPL) got off to a rough start in 2022, as investors continued their transition away from tech stocks and into value-oriented companies in order to combat rising interest
This Tech Stock May Be Criminally Underrated
Collaboration software company Atlassian (NASDAQ: TEAM) crushed its latest earnings report in several categories, but one segment's numbers especially stood out. In this episode of "3 Minute Stocks
Will Novavax Stock Ever Hit $300 Again?
On Feb. 8 of last year, shares of the coronavirus vaccine developer Novavax (NASDAQ: NVAX) commanded a price near $319, with the market's fervor for its jab feeding more and more into the hype. Of